CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

CEL-SCI Price Performance

CVM opened at $0.21 on Friday. The company’s 50-day simple moving average is $0.33 and its two-hundred day simple moving average is $0.58. CEL-SCI has a 52-week low of $0.18 and a 52-week high of $2.39. The stock has a market capitalization of $16.71 million, a P/E ratio of -0.43 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07.

Institutional Trading of CEL-SCI

A hedge fund recently raised its stake in CEL-SCI stock. Thoroughbred Financial Services LLC boosted its position in CEL-SCI Co. (NYSE:CVM) by 40.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 191,661 shares of the company’s stock after purchasing an additional 54,900 shares during the period. Thoroughbred Financial Services LLC owned about 0.26% of CEL-SCI worth $76,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.